Literature DB >> 33410134

Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics.

Alan S Perelson1,2, Ruian Ke1,2.   

Abstract

Modern viral kinetic modeling and its application to therapeutics is a field that attracted the attention of the medical, pharmaceutical, and modeling communities during the early days of the AIDS epidemic. Its successes led to applications of modeling methods not only to HIV but a plethora of other viruses, such as hepatitis C virus (HCV), hepatitis B virus and cytomegalovirus, which along with HIV cause chronic diseases, and viruses such as influenza, respiratory syncytial virus, West Nile virus, Zika virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which generally cause acute infections. Here we first review the historical development of mathematical models to understand HIV and HCV infections and the effects of treatment by fitting the models to clinical data. We then focus on recent efforts and contributions of applying these models towards understanding SARS-CoV-2 infection and highlight outstanding questions where modeling can provide crucial insights and help to optimize nonpharmaceutical and pharmaceutical interventions of the coronavirus disease 2019 (COVID-19) pandemic. The review is written from our personal perspective emphasizing the power of simple target cell limited models that provided important insights and then their evolution into more complex models that captured more of the virology and immunology. To quote Albert Einstein, "Everything should be made as simple as possible, but not simpler," and this idea underlies the modeling we describe below.
© 2021 The Authors. Clinical Pharmacology & Therapeutics © 2021 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33410134      PMCID: PMC8142935          DOI: 10.1002/cpt.2160

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  105 in total

1.  Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.

Authors:  Eva Herrmann; Stefan Zeuzem; Christoph Sarrazin; Holger Hinrichsen; Yves Benhamou; Michael P Manns; Markus Reiser; Henk Reesink; José L Calleja; Xavier Forns; Gerhard G Steinmann; Gerhard Nehmiz
Journal:  Antivir Ther       Date:  2006

Review 2.  Dynamics of HIV-1 and CD4+ lymphocytes in vivo.

Authors:  A S Perelson; P Essunger; D D Ho
Journal:  AIDS       Date:  1997       Impact factor: 4.177

3.  Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay.

Authors:  A V Herz; S Bonhoeffer; R M Anderson; R M May; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  Mathematical modelling identifies the role of adaptive immunity as a key controller of respiratory syncytial virus in cotton rats.

Authors:  Darren Wethington; Olivia Harder; Karthik Uppulury; William C L Stewart; Phylip Chen; Tiffany King; Susan D Reynolds; Alan S Perelson; Mark E Peeples; Stefan Niewiesk; Jayajit Das
Journal:  J R Soc Interface       Date:  2019-11-27       Impact factor: 4.118

5.  IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes.

Authors:  Rudragouda Channappanavar; Anthony R Fehr; Jian Zheng; Christine Wohlford-Lenane; Juan E Abrahante; Matthias Mack; Ramakrishna Sompallae; Paul B McCray; David K Meyerholz; Stanley Perlman
Journal:  J Clin Invest       Date:  2019-07-29       Impact factor: 14.808

6.  Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance.

Authors:  Hulin Wu; Yangxin Huang; Edward P Acosta; Susan L Rosenkranz; Daniel R Kuritzkes; Joseph J Eron; Alan S Perelson; John G Gerber
Journal:  J Acquir Immune Defic Syndr       Date:  2005-07-01       Impact factor: 3.731

7.  Virological assessment of hospitalized patients with COVID-2019.

Authors:  Roman Wölfel; Victor M Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Müller; Daniela Niemeyer; Terry C Jones; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner
Journal:  Nature       Date:  2020-04-01       Impact factor: 49.962

8.  Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.

Authors:  Tyler N Starr; Allison J Greaney; Amin Addetia; William W Hannon; Manish C Choudhary; Adam S Dingens; Jonathan Z Li; Jesse D Bloom
Journal:  Science       Date:  2021-01-25       Impact factor: 47.728

9.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.

Authors:  Johanna Hansen; Alina Baum; Kristen E Pascal; Vincenzo Russo; Stephanie Giordano; Elzbieta Wloga; Benjamin O Fulton; Ying Yan; Katrina Koon; Krunal Patel; Kyung Min Chung; Aynur Hermann; Erica Ullman; Jonathan Cruz; Ashique Rafique; Tammy Huang; Jeanette Fairhurst; Christen Libertiny; Marine Malbec; Wen-Yi Lee; Richard Welsh; Glen Farr; Seth Pennington; Dipali Deshpande; Jemmie Cheng; Anke Watty; Pascal Bouffard; Robert Babb; Natasha Levenkova; Calvin Chen; Bojie Zhang; Annabel Romero Hernandez; Kei Saotome; Yi Zhou; Matthew Franklin; Sumathi Sivapalasingam; David Chien Lye; Stuart Weston; James Logue; Robert Haupt; Matthew Frieman; Gang Chen; William Olson; Andrew J Murphy; Neil Stahl; George D Yancopoulos; Christos A Kyratsous
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

10.  SARS-CoV-2 viral load is associated with increased disease severity and mortality.

Authors:  Jesse Fajnzylber; James Regan; Kendyll Coxen; Heather Corry; Colline Wong; Alexandra Rosenthal; Daniel Worrall; Francoise Giguel; Alicja Piechocka-Trocha; Caroline Atyeo; Stephanie Fischinger; Andrew Chan; Keith T Flaherty; Kathryn Hall; Michael Dougan; Edward T Ryan; Elizabeth Gillespie; Rida Chishti; Yijia Li; Nikolaus Jilg; Dusan Hanidziar; Rebecca M Baron; Lindsey Baden; Athe M Tsibris; Katrina A Armstrong; Daniel R Kuritzkes; Galit Alter; Bruce D Walker; Xu Yu; Jonathan Z Li
Journal:  Nat Commun       Date:  2020-10-30       Impact factor: 14.919

View more
  14 in total

Review 1.  Aerosol Transport Modeling: The Key Link Between Lung Infections of Individuals and Populations.

Authors:  Chantal Darquenne; Azadeh A T Borojeni; Mitchel J Colebank; M Gregory Forest; Balázs G Madas; Merryn Tawhai; Yi Jiang
Journal:  Front Physiol       Date:  2022-06-20       Impact factor: 4.755

2.  Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms.

Authors:  Budhaditya Chatterjee; Harshbir Singh Sandhu; Narendra M Dixit
Journal:  PLoS Pathog       Date:  2022-06-27       Impact factor: 7.464

3.  Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness.

Authors:  Ruian Ke; Pamela P Martinez; Rebecca L Smith; Laura L Gibson; Agha Mirza; Madison Conte; Nicholas Gallagher; Chun Huai Luo; Junko Jarrett; Ruifeng Zhou; Abigail Conte; Tongyu Liu; Mireille Farjo; Kimberly K O Walden; Gloria Rendon; Christopher J Fields; Leyi Wang; Richard Fredrickson; Darci C Edmonson; Melinda E Baughman; Karen K Chiu; Hannah Choi; Kevin R Scardina; Shannon Bradley; Stacy L Gloss; Crystal Reinhart; Jagadeesh Yedetore; Jessica Quicksall; Alyssa N Owens; John Broach; Bruce Barton; Peter Lazar; William J Heetderks; Matthew L Robinson; Heba H Mostafa; Yukari C Manabe; Andrew Pekosz; David D McManus; Christopher B Brooke
Journal:  Nat Microbiol       Date:  2022-04-28       Impact factor: 30.964

4.  Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019.

Authors:  James Regan; James P Flynn; Alexandra Rosenthal; Hannah Jordan; Yijia Li; Rida Chishti; Francoise Giguel; Heather Corry; Kendyll Coxen; Jesse Fajnzylber; Elizabeth Gillespie; Daniel R Kuritzkes; Nir Hacohen; Marcia B Goldberg; Michael R Filbin; Xu G Yu; Lindsey Baden; Ruy M Ribeiro; Alan S Perelson; Jessica M Conway; Jonathan Z Li
Journal:  Open Forum Infect Dis       Date:  2021-04-17       Impact factor: 3.835

Review 5.  Advancing therapies for viral infections using mechanistic computational models of the dynamic interplay between the virus and host immune response.

Authors:  Veronika I Zarnitsyna; Juliano Ferrari Gianlupi; Amit Hagar; T J Sego; James A Glazier
Journal:  Curr Opin Virol       Date:  2021-08-24       Impact factor: 7.090

6.  Comparing antiviral strategies against COVID-19 via multiscale within-host modelling.

Authors:  F Fatehi; R J Bingham; E C Dykeman; P G Stockley; R Twarock
Journal:  R Soc Open Sci       Date:  2021-08-11       Impact factor: 2.963

7.  An age-structured model of hepatitis B viral infection highlights the potential of different therapeutic strategies.

Authors:  Farzad Fatehi; Richard J Bingham; Peter G Stockley; Reidun Twarock
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.996

8.  Modeling insights into SARS-CoV-2 respiratory tract infections prior to immune protection.

Authors:  Alexander Chen; Timothy Wessler; Katherine Daftari; Kameryn Hinton; Richard C Boucher; Raymond Pickles; Ronit Freeman; Samuel K Lai; M Gregory Forest
Journal:  Biophys J       Date:  2022-04-02       Impact factor: 3.699

9.  Spatially distributed infection increases viral load in a computational model of SARS-CoV-2 lung infection.

Authors:  Melanie E Moses; Steven Hofmeyr; Judy L Cannon; Akil Andrews; Rebekah Gridley; Monica Hinga; Kirtus Leyba; Abigail Pribisova; Vanessa Surjadidjaja; Humayra Tasnim; Stephanie Forrest
Journal:  PLoS Comput Biol       Date:  2021-12-23       Impact factor: 4.475

10.  Impairment of T cells' antiviral and anti-inflammation immunities may be critical to death from COVID-19.

Authors:  Luhao Zhang; Rong Li; Gang Song; Gregory D Scholes; Zhen-Su She
Journal:  R Soc Open Sci       Date:  2021-12-22       Impact factor: 2.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.